ERIN MCCASLAND: Open Payments
NPI 1417416819 · TEXARKANA, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$930 in 32 payments from 11 companies in 2025. Trend: 2023 $520 · 2024 $869 · 2025 $930
Food & beverage: $851Education: $79
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 13 | $320 |
| United Therapeutics Corporation | 3 | $183 |
| Regeneron Healthcare Solutions, Inc. | 5 | $144 |
| SANOFI-AVENTIS U.S. LLC | 1 | $79 |
| Verona Pharma, Inc. | 3 | $52 |
| Actelion Pharmaceuticals US, Inc. | 2 | $47 |
| Viatris Specialty LLC | 1 | $34 |
| Merck Sharp & Dohme LLC | 1 | $21 |
| Amgen Inc. | 1 | $17 |
| Grifols USA, LLC | 1 | $16 |
Products named: DUPIXENT, Tyvaso, BREZTRI, TEZSPIRE, FASENRA, Ohtuvayre, YUPELRI, OPSYNVI.
Industry payments across TX — which companies pay providers there.
